NCT04238845

Brief Summary

Malaria and malnutrition represent major public health concerns worldwide especially in Sub-Sahara Africa. Despite implementation of Seasonal Malaria Chemoprophylaxis (SMC), an intervention aimed at reducing malaria prevalence among children aged 6- 59 months, the burden of malaria and associated mortality among children below age 5 years remains high in Burkina Faso. This raises the question of what hiding factors may negatively affect the responsiveness of SMC intervention. Malnutrition, in particular micronutrient deficiency, is one of these potential factors that can negatively affect the effectiveness of SMC. Treating micronutrient deficiencies is known to reduce the prevalence of malaria mortality in highly prevalent malaria zone such as rural settings. Therefore, the hypothesis that a combined strategy of SMC together with a daily oral nutrients supplement (Vitamin A-Zinc OR fortified peanut butter-like paste-Plumpy'Doz) will enhance the immune response and decrease the incidence of malaria in this population and at the same time reduce the burden of malnutrition among children under SMC coverage was postulated. Prior to the SMC implementation by the National Malaria Control Program (NMCP), children under SMC coverage will be identified through the Health and Demographic Surveillance System (HDSS). Children will be randomly assigned to one of the three groups (a) SMC + Vitamin A alone, (b) SMC + Vitamin A+ Zinc, or (c) SMC+Vitamin A + Plumpy'Doz. After each SMC monthly distribution, children will be visited at home to confirm drug administration and follow-up for one year. Anthropometric indicators will be recorded at each visit. Blood samples will be collected for thick and thin film and hemoglobin measurement and spotted onto filter paper for further PCR analyses. This project will serve as a pilot of an integrated strategy in order to mutualize resources for best impact. By relying on existing strategies, the policy implementation of this joint intervention will be scalable at country and regional levels.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,059

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 15, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 23, 2020

Completed
6 months until next milestone

Study Start

First participant enrolled

July 13, 2020

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 4, 2021

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
Last Updated

March 8, 2022

Status Verified

March 1, 2021

Enrollment Period

12 months

First QC Date

January 15, 2020

Last Update Submit

March 7, 2022

Conditions

Keywords

MalariaMalnutritionChemoprevention

Outcome Measures

Primary Outcomes (4)

  • The relative risk of the incidence of clinical malaria

    The ration of the number of malaria cases in intervention over comparator arm hospitalisation and mortality in SMC group compared to SMC + supplement groups

    One year

  • The mid-upper arm circumference gain

    The difference between baseline MUAC and MUAC at the end of the study period in the intervention groups compared to the control group

    One year

  • Weight gain

    Difference between weight at baseline and weight at the end of the study

    One year

  • prevalence of anemia

    prevalence of anemia in each arm

    one year

Secondary Outcomes (7)

  • The prevalence of mutant pfcrt allele

    One year

  • The prevalence of mutant pfmdr1 allele

    One year

  • The prevalence of mutant dhfr allele

    One year

  • The prevalence of mutant dhps allele

    One year

  • SMC coverage

    Six months

  • +2 more secondary outcomes

Study Arms (3)

SMC + Vitamin A alone

ACTIVE COMPARATOR

Children under SMC Coverage, receiving AQSP and Vitamin A supplementation alone

Drug: AQSP AdministrationDietary Supplement: Supplementation with Vitamin A

SMC+ Vitamin A + Plumpy'Doz

EXPERIMENTAL

Children under SMC Coverage, receiving AQSP + Vitamin A plus Plumpy'Doz supplementation

Drug: AQSP AdministrationDietary Supplement: Supplementation with Plumpy'DozDietary Supplement: Supplementation with Vitamin A

SMC+ Vitamin A + Zinc

EXPERIMENTAL

Children under SMC Coverage, receiving AQSP + Vitamin A plus Zinc supplementation

Drug: AQSP AdministrationDietary Supplement: Supplementation with Vitamin ADietary Supplement: Supplementation with Zinc

Interventions

Three days treatment of all children with AQSP for SMC

SMC + Vitamin A aloneSMC+ Vitamin A + Plumpy'DozSMC+ Vitamin A + Zinc

Daily supplementation of children with Plumpy'Doz

SMC+ Vitamin A + Plumpy'Doz

Single dose supplementation with Vitamin A to all children

SMC + Vitamin A aloneSMC+ Vitamin A + Plumpy'DozSMC+ Vitamin A + Zinc
Supplementation with ZincDIETARY_SUPPLEMENT

Daily supplementation with Zinc

SMC+ Vitamin A + Zinc

Eligibility Criteria

Age6 Months - 59 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Children under SMC coverage (6-59months old),
  • living within the HDSS coverage area,
  • ability to complete the study follow-up period,
  • written consent obtained from parents

You may not qualify if:

  • individual not under SMC coverage,
  • Children under SMC coverage who did not receive the treatment (Amodiaquine-Sulfadoxine-Pyrimethamine) or the Vitamin Supplementation,
  • ill individual at the time of the enrolment including uncomplicated/severe malaria or severe malnutrition,
  • known allergy to Vitamin A or Zinc or Plumpy'Doz,
  • planned travel or inability to complete the study follow-up,
  • and unwillingness to participate to the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut de Recherche en Sciences de la Santé/ Clinical Research Unit of Nanoro

Ouagadougou, Kadiogo, 218 CMS 11, Burkina Faso

Location

Related Publications (2)

  • Sondo P, Kabore B, Rouamba T, Compaore E, Tibiri YNG, Kabore HALF, Derra K, Tahita MC, Ilboudo H, Tougri G, Bouda I, Dakyo T, Kafando H, Ouedraogo F, Rouamba E, Hien SF, Kazienga A, Compaore CS, Bambara E, Nana M, Dahal P, Garanet F, Kabore W, Lefevre T, Guerin P, Tinto H. Enhanced effect of seasonal malaria chemoprevention when coupled with nutrients supplementation for preventing malaria in children under 5 years old in Burkina Faso: a randomized open label trial. Malar J. 2023 Oct 18;22(1):315. doi: 10.1186/s12936-023-04745-6.

  • Sondo P, Tahita MC, Rouamba T, Derra K, Kabore B, Compaore CS, Ouedraogo F, Rouamba E, Ilboudo H, Bambara EA, Nana M, Sawadogo EY, Sorgho H, Some AM, Valea I, Dahal P, Traore/Coulibaly M, Tinto H. Assessment of a combined strategy of seasonal malaria chemoprevention and supplementation with vitamin A, zinc and Plumpy'Doz to prevent malaria and malnutrition in children under 5 years old in Burkina Faso: a randomized open-label trial (SMC-NUT). Trials. 2021 May 24;22(1):360. doi: 10.1186/s13063-021-05320-7.

MeSH Terms

Conditions

MalariaChild Nutrition DisordersMalnutrition

Interventions

Dietary SupplementsVitamin AZinc

Condition Hierarchy (Ancestors)

Protozoan InfectionsParasitic DiseasesInfectionsMosquito-Borne DiseasesVector Borne DiseasesNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

FoodDiet, Food, and NutritionPhysiological PhenomenaFood and BeveragesRetinoidsCarotenoidsPolyenesAlkenesHydrocarbons, AcyclicHydrocarbonsOrganic ChemicalsCyclohexenesCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicTerpenesDiterpenesPigments, BiologicalBiological FactorsMetals, HeavyElementsInorganic ChemicalsTransition ElementsMetals

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 15, 2020

First Posted

January 23, 2020

Study Start

July 13, 2020

Primary Completion

July 4, 2021

Study Completion

March 1, 2022

Last Updated

March 8, 2022

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will share

Data on Plasmodium resistance will be shared with Infectious Diseases Data Observatory (IDDO)/ WorldWide Antimalarial Resistance Network (WWARN). The WHO will have access to the data to facilitate the development of new malaria control policy. Data will be made available to partners and as well as for other interested groups through the IDDO platform.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
Data will be shared within a year after database lock for unlimited time
Access Criteria
free access

Locations